Skip to main content

Table 1 Patient profiles

From: Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

CharacteristicValue
Total number of patients31
Age (year)55.1 ± 15.5 (16.0–81.0)
Gender (M:F)12:19
ECOG performance status
 08 (25.8%)
 123 (74.2%)
Primary tumour site
 Pancreas17 (54.8%)
 Stomach5 (16.1%)
 Small bowel2 (6.5%)
 Rectum4 (12.9%)
 Unknown3 (9.7%)
Differentiation of tumour
 Well-differentiated31 (100.0%)
NET WHO grade
 18 (25.8%)
 220 (64.5%)
 32 (6.5%)
 Unknown1 (3.2%)
Median Ki-67 index (%)7.5 (0.5–25.0)
Existence of carcinoid symptoms8 (25.8%)
Previous treatment
 Surgery14 (45.2%)
 Chemotherapy4 (12.9%)
Hepatic tumour volume assessed by CT or MRI
 0–25%15 (48.4%)
 > 25%10 (32.2%)
 Unknown6 (19.4%)
Best response after lanreotide therapy
 Partial response1 (3.2%)
 Stable disease28 (90.3%)
 Progressive disease2 (6.5%)
Progression of disease after lanreotide therapy20 (64.5%)
Median PFS after lanreotide therapy (months)14.4 (1.3–34.9)
  1. ECOG Eastern Cooperative Oncology Group, NET neuroendocrine tumour, WHO World Health Organization, CT computed tomography, MRI magnetic resonance imaging, PFS progression-free survival